These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 443660)

  • 1. Drug evaluation after marketing.
    Slone D; Shapiro S; Miettinen OS; Finkle WD; Stolley PD
    Ann Intern Med; 1979 Feb; 90(2):257-61. PubMed ID: 443660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122
    [No Abstract]   [Full Text] [Related]  

  • 3. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
    Simmons HE
    Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
    [No Abstract]   [Full Text] [Related]  

  • 4. Assuring the safety and efficacy of therapies.
    Stolley PD
    Int J Health Serv; 1974; 4(1):131-45. PubMed ID: 4597990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
    Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
    Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [International efforts in the field of drug safety].
    Bertaux JF
    Soz Praventivmed; 1980 Mar; 25(1-2):23-5. PubMed ID: 7424174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What to do until the FDA arrives.
    Riegelman RK
    Postgrad Med; 1981 Dec; 70(6):103-8. PubMed ID: 7031627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Change of Reference to Post-Marketing Surveillance Based on the Sequence of Revising the Pharmaceutical Affairs Law.
    Takahashi H
    Yakushigaku Zasshi; 2016; 51(1):29-39. PubMed ID: 30183145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-marketing surveillance of adverse reactions to new medicines.
    Wilson AB
    Br Med J; 1977 Oct; 2(6093):1001-3. PubMed ID: 922357
    [No Abstract]   [Full Text] [Related]  

  • 10. [How to improve drug development and utilization in pediatrics].
    Pons G; Lassale C; Eschwege E
    Therapie; 1999; 54(4):423-32. PubMed ID: 10667109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review and critique of the Institute of Medicine report "the future of drug safety".
    Benet LZ
    Clin Pharmacol Ther; 2007 Feb; 81(2):158-61. PubMed ID: 17259941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of marketed drugs in the United Kingdom.
    Cuthbert MF; Cone MD
    Agents Actions; 1978 Jun; 8(4):412-3. PubMed ID: 685778
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective.
    Bakke OM; Manocchia M; de Abajo F; Kaitin KI; Lasagna L
    Clin Pharmacol Ther; 1995 Jul; 58(1):108-17. PubMed ID: 7628177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of newly approved drugs: implications for prescribing.
    Temple RJ; Himmel MH
    JAMA; 2002 May; 287(17):2273-5. PubMed ID: 11980528
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulatory concerns at various phases of drug development.
    Aurecchia S; Orloff D; Sobel S
    Am J Cardiol; 1998 Apr; 81(8A):2F-4F. PubMed ID: 9604895
    [No Abstract]   [Full Text] [Related]  

  • 16. A time-indexed reference standard of adverse drug reactions.
    Harpaz R; Odgers D; Gaskin G; DuMouchel W; Winnenburg R; Bodenreider O; Ripple A; Szarfman A; Sorbello A; Horvitz E; White RW; Shah NH
    Sci Data; 2014 Nov; 1():140043. PubMed ID: 25632348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug events: identification and attribution.
    Rogers AS
    Drug Intell Clin Pharm; 1987 Nov; 21(11):915-20. PubMed ID: 3678067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory advice on evaluation of the proarrhythmic potential of drugs.
    Stockbridge N; Throckmorton DC
    J Electrocardiol; 2004; 37 Suppl():40-1. PubMed ID: 15534791
    [No Abstract]   [Full Text] [Related]  

  • 19. Post-marketing surveillance.
    Lasagna L
    Triangle; 1980; 19(3-4):107-11. PubMed ID: 7013216
    [No Abstract]   [Full Text] [Related]  

  • 20. Post-marketing surveillance of licensed medicinal and other products.
    Griffin JP
    Health Bull (Edinb); 1981 Nov; 39(6):356-66. PubMed ID: 7035401
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.